Evidence map›Paper›PMID 25613922›Full record

Trial reportHepatology (Baltimore, Md.)2015

Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis.

Cynthia Tsien, Gangarao Davuluri, Dharmvir Singh, Allawy Allawy, Gabriella A M Ten Have, Samjhana Thapaliya, John M Schulze, David Barnes, Arthur J McCullough, Marielle P K J Engelen and 2 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Hepatology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03605147 (The Effect of Calcium β-hydroxy-β-methylbutyrate Supplementation in Sarcopenia in Liver Cirrhosis:A Randomized Double-blind Controlled Trial), which is not on this map. Cited by 112 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 4 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03605147 naunknown statusnot on this mapstarted 2018, after this paper: background citation

The Effect of Calcium β-hydroxy-β-methylbutyrate Supplementation in Sarcopenia in Liver Cirrhosis:A Randomized Double-blind Controlled Trial

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2018 to 2019Enrolled120ConditionsSarcopenia, Cirrhosis, LiverArmsCaHMB, Placebo
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 4 syntheses or guidelines pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. ESPEN guideline on clinical nutrition in liver disease.Clinical nutrition (Edinburgh, Scotland) · 2019
    Guideline
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Cynthia TsienDepartments of Gastroenterology, Toronto General Hospital, Toronto, Canada.
Gangarao DavuluriDepartment of Pathobiology, Cleveland Clinic, Cleveland, OH.
Dharmvir SinghDepartments of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH.
Allawy AllawyDepartment of Pathobiology, Cleveland Clinic, Cleveland, OH.
Gabriella A M Ten HaveDepartment of Kinesiology, Texas A&M University, College Station, TX.
Samjhana ThapaliyaDepartments of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH.
John M SchulzeMolecular Structure Facility, University of California, Davis, CA.
David BarnesDepartments of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH.
Arthur J McCulloughDepartment of Pathobiology, Cleveland Clinic, Cleveland, OH.
Marielle P K J EngelenDepartment of Kinesiology, Texas A&M University, College Station, TX.
Nicolaas E P DeutzDepartment of Kinesiology, Texas A&M University, College Station, TX.
Srinivasan DasarathyDepartment of Pathobiology, Cleveland Clinic, Cleveland, OH.
Cleveland Clinic · USTexas A&M University · USToronto General Hospital · CAUniversity of California, Davis · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Non Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2M
Novel Therapies for Alcoholic HepatitisU01AA021893 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI MCCLAIN, CRAIG J., MCCULLOUGH, ARTHUR JOSEPH · 2012 to 2017
$6.0M
Pilot ProjectP20AA017837 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI FELDSTEIN, ARIEL · 2009 to 2013
$2.2M
Mechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01DK083414 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2011 to 2015
$1.8M
Alcohol induces muscle autophagy by a novel AMPK independent PI3K mediated mechanR21AA022742 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2014 to 2015
$410k
NCATS NIH HHS UL1 TR000439NCRR NIH HHS 1UL1RR024989NIAAA NIH HHS P20 AA017837NIAAA NIH HHS R21 AA022742NIAAA NIH HHS U01 AA021893NIAAA NIH HHS U01AA021893NIDDK NIH HHS R01 DK083414NIDDK NIH HHS R01 DK 83414NIDDK NIH HHS U01 DK061732
6 · The paper itself

Abstract

unlabelledSkeletal muscle loss (sarcopenia) is a major clinical complication in alcoholic cirrhosis with no effective therapy. Skeletal muscle autophagic proteolysis and myostatin expression (inhibitor of protein synthesis) are increased in cirrhosis and believed to contribute to anabolic resistance. A prospective study was performed to determine the mechanisms of sarcopenia in alcoholic cirrhosis and potential reversal by leucine. In six well-compensated, stable, alcoholic patients with cirrhosis and eight controls, serial vastus lateralis muscle biopsies were obtained before and 7 hours after a single oral branched chain amino acid mixture enriched with leucine (BCAA/LEU). Primed-constant infusion of l-[ring-(2) H5 ]-phenylalanine was used to quantify whole-body protein breakdown and muscle protein fractional synthesis rate using liquid chromatography/mass spectrometry. Muscle expression of myostatin, mammalian target of rapamycin (mTOR) targets, autophagy markers, protein ubiquitination, and the intracellular amino acid deficiency sensor general control of nutrition 2 were quantified by immunoblots and the leucine exchanger (SLC7A5) and glutamine transporter (SLC38A2), by real-time polymerase chain reaction. Following oral administration, plasma BCAA concentrations showed a similar increase in patients with cirrhosis and controls. Skeletal muscle fractional synthesis rate was 9.63 ± 0.36%/hour in controls and 9.05 ± 0.68%/hour in patients with cirrhosis (P = 0.54). Elevated whole-body protein breakdown in patients with cirrhosis was reduced with BCAA/LEU (P = 0.01). Fasting skeletal muscle molecular markers showed increased myostatin expression, impaired mTOR signaling, and increased autophagy in patients with cirrhosis compared to controls (P < 0.01). The BCAA/LEU supplement did not alter myostatin expression, but mTOR signaling, autophagy measures, and general control of nutrition 2 activation were consistently reversed in cirrhotic muscle (P < 0.01). Expression of SLC7A5 was higher in the basal state in patients with cirrhosis than controls (P < 0.05) but increased with BCAA/LEU only in controls (P < 0.001).

conclusionsImpaired mTOR1 signaling and increased autophagy in skeletal muscle of patients with alcoholic cirrhosis is acutely reversed by BCAA/LEU.

Indexed as

AdultAutophagyCase-Control StudiesFemaleHumansLeucineLiver Cirrhosis, AlcoholicMaleMiddle AgedMuscle ProteinsMuscle, SkeletalPhenylalanineProspective StudiesProteolysisSarcopeniaTOR Serine-Threonine KinasesLeucineMTOR protein, humanMuscle ProteinsPhenylalanineTOR Serine-Threonine Kinases

Identifiers

PMID25613922
PMCPMC4441611
OpenAlexW1619454850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.